{"protocolSection":{"identificationModule":{"nctId":"NCT00621049","orgStudyIdInfo":{"id":"SCRI LUN 142"},"secondaryIdInfos":[{"id":"US_IST_12218"},{"id":"AVF3923s"}],"organization":{"fullName":"SCRI Development Innovations, LLC","class":"OTHER"},"briefTitle":"Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC","officialTitle":"Randomized Phase II Trial of Adjuvant Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Patients With Resected Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2015-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-12"},"primaryCompletionDateStruct":{"date":"2013-07","type":"ACTUAL"},"completionDateStruct":{"date":"2014-02","type":"ACTUAL"},"studyFirstSubmitDate":"2007-12-26","studyFirstSubmitQcDate":"2008-02-21","studyFirstPostDateStruct":{"date":"2008-02-22","type":"ESTIMATED"},"resultsFirstSubmitDate":"2015-04-24","resultsFirstSubmitQcDate":"2015-04-24","resultsFirstPostDateStruct":{"date":"2015-05-14","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-05-13","lastUpdatePostDateStruct":{"date":"2015-06-08","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"SCRI Development Innovations, LLC","class":"OTHER"},"collaborators":[{"name":"Genentech, Inc.","class":"INDUSTRY"},{"name":"Sanofi","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"Multicenter randomized phase II trial to examine the safety and efficacy of carboplatin, docetaxel, bevacizumab followed by maintenance bevacizumab and erlotinib in patients with completely resected stage IB, II, and select III NSCLC."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"],"keywords":["Non-Small Cell Lung Cancer","Resected","Carboplatin","Docetaxel","Bevacizumab","Erlotinib"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":112,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Docetaxel/Carboplatin/Bevacizumab/Erlotinib","type":"EXPERIMENTAL","interventionNames":["Drug: Docetaxel/Carboplatin/Bevacizumab/Erlotinib"]},{"label":"Docetaxel and Carboplatin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Docetaxel/Carboplatin"]}],"interventions":[{"type":"DRUG","name":"Docetaxel/Carboplatin/Bevacizumab/Erlotinib","description":"Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1 Bevacizumab 15mg/kg IV D1\n\nDocetaxel should be administered before carboplatin.\n\nAfter completion of four cycles of treatment, patients in Cohort A will then proceed with Maintenance treatment defined as follows:\n\nMaintenance Treatment for patients in Cohort A:\n\nBevacizumab 15mg/kg IV D1 Erlotinib 150mg PO daily\n\nTreatment cycle = 21 days. Patients will complete 8 cycles (24 weeks) of maintenance therapy unless there is evidence of disease recurrence or unacceptable toxicity.","armGroupLabels":["Docetaxel/Carboplatin/Bevacizumab/Erlotinib"]},{"type":"DRUG","name":"Docetaxel/Carboplatin","description":"Adjuvant Treatment Cohort B:\n\nDocetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1\n\nDocetaxel should be administered before carboplatin.\n\nTreatment cycle = 21 days. Patients in Cohort B will complete 4 cycles of treatment.","armGroupLabels":["Docetaxel and Carboplatin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Disease-free Survival","description":"The length of time, in months, that patients were alive from the end of their treatment without any signs or symptoms of their disease.","timeFrame":"1 year"}],"secondaryOutcomes":[{"measure":"Safety","description":"Adverse Events occuring in \\>15% of patients","timeFrame":"2 years"},{"measure":"2-year Survival","description":"Proportion of patients known to still be alive 2 years after coming on study","timeFrame":"24 months"},{"measure":"Overall Survival (OS)","description":"The Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death","timeFrame":"18 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients must have histologically-confirmed non-small cell lung cancer (adenocarcinoma, squamous, large cell and undifferentiated). Mixed small cell and non-small histologies are excluded.\n2. Patients with completely resected (R0) stage IB, II, and select III NSCLC. The following stages are eligible:\n\n   IB T2 N0 IIA T1 N1 IIB T2 N1 IIB T3 N0 IIIA T3 N1\n   * Bronchioalveolar carcinoma that presents as a single, solitary discrete nodule or mass may be included\n   * Patients determined to have N2 disease, that was not apparent radiologically preoperatively (and completely resected) can be included.\n3. Complete surgical resection defined as the appropriate pulmonary parenchymal resection including lobectomy, bilobectomy, sleeve lobectomy, and pneumonectomy with histologically confirmed negative bronchial margins. Patients treated by segmentectomy or wedge resection are not eligible for this study. Additionally all patients must have had either a mediastinal node dissection or at least, sampling of 2 mediastinal nodal stations (levels 4,7,and 9 for right-sided tumors, and levels 5,6,7, and 9 for left-sided tumors are suggested.)\n4. No evidence of metastatic disease\n5. ANC \\>= 1500, platelets \\>= 100,000 and hemoglobin \\>= 10.0.\n6. Total bilirubin \\<= ULN. AST and ALT and alkaline phosphatase must be WNL\n7. Serum creatinine \\<= 1.5mg/dl (If greater than 1.5, the creatinine clearance, calculated according to the Cockroft-Gault formula, must be \\>= 50ml/min).\n8. Patients may have had no previous chemotherapy, radiation therapy, angiogenesis inhibitor, or tyrosine kinase inhibitor for non-small cell lung cancer.\n9. Patients must be able to understand the nature of this study and give written informed consent.\n10. Age \\>= 18 years\n11. Ability to start treatment between 8 and 12 weeks following surgery.\n12. Ability to take oral medication.\n\nExclusion Criteria:\n\n1. Patients with preoperative radiologic evidence of N2 disease by either PET or CT scan (i.e. radiological evidence of metastasis to ipsilateral mediastinal and subcarinal nodes) that is confirmed as N2 disease histologically are excluded. - PLEASE SEE EXCEPTION in section 3.1.2 of protocol\n2. Mixed small cell and non-small cell histologies\n3. Pulmonary carcinoid tumors\n4. Positive bronchial margins\n5. History of prior malignancy within 5 years with the exception of skin cancer or cervical carcinoma in situ.\n6. Women who are pregnant (positive pregnancy test) or breast-feeding. Subjects of childbearing potential or with partners of childbearing potential (women and men) must use effective birth control measures during treatment.\n7. Treatment with a non-approved or investigational drug within 30 days before day 1 of trial treatment.\n8. Patients with seizures not controlled with standard medical therapy.\n9. Patients with active infection requiring parenteral antibiotics\n10. Patients who have had major surgical procedure, open biopsy, or significant traumatic injury within 8 weeks of beginning study treatment or anticipation of need for major surgical procedure during the course of the study\n11. Fine needle aspiration, core biopsy or other minor surgical procedure (excluding placement of a vascular access device) within 7 days of beginning study treatment.\n12. Patients receiving thrombolytic therapy within 10 days of starting study treatment are also ineligible. Patients may receive prophylactic anticoagulation therapy, 1 mg coumadin daily for port clot prophylaxis.\n13. Patients with proteinuria at screening as demonstrated by either:\n\n    * Urine protein creatinine (UPC) ratio \\>= 1.0 at screening OR\n    * Urine dipstick for proteinuria \\>= 2+ (patients discovered to have \\>= 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate \\>= 1 g of protein in 24hours to be eligible).\n14. Patients with serious nonhealing wound, ulcer, or bone fracture.\n15. Patients with evidence of bleeding diathesis or coagulopathy.\n16. Patients with history of hemoptysis defined as bright red blood of Â½ teaspoon or more per episode) within 8 weeks prior to study treatment.\n17. History of myocardial infarction or unstable angina within 6 months of beginning study treatment.\n18. Inadequately controlled hypertension (defined as systolic blood pressure \\> 150 and /or diastolic blood pressure \\> 100 mmHg on antihypertensive medications).\n19. New York Heart Association (NYHA) grade II or greater CHF.\n20. Serious cardiac arrhythmia requiring medication.\n21. Symptomatic peripheral vascular disease.\n22. History of stroke or transient ischemic attack within 6 months prior to beginning bevacizumab.\n23. Any prior history of hypertensive crisis or hypertensive encephalopathy.\n24. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to beginning study treatment.\n25. ECOG Performance status \\> 1.\n26. Peripheral neuropathy\\> grade 1.\n27. Known hypersensitivity to any component of study drugs including platinum or to drugs formulated with polysorbate 80.\n28. Impaired oral absorption.\n29. Inability to comply with study and/or follow-up procedures.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"David Spigel, M.D.","affiliation":"SCRI Development Innovations, LLC","role":"STUDY_CHAIR"}],"locations":[{"facility":"Northeast Alabama Medical Center","city":"Anniston","state":"Alabama","zip":"36207","country":"United States","geoPoint":{"lat":33.65983,"lon":-85.83163}},{"facility":"Northeast Arkansas Clinic","city":"Jonesboro","state":"Arkansas","zip":"72401","country":"United States","geoPoint":{"lat":35.8423,"lon":-90.70428}},{"facility":"Florida Cancer Specialists","city":"Fort Myers","state":"Florida","zip":"33901","country":"United States","geoPoint":{"lat":26.62168,"lon":-81.84059}},{"facility":"Gulfcoast Oncology Associates","city":"St. Petersburg","state":"Florida","zip":"33705","country":"United States","geoPoint":{"lat":27.77086,"lon":-82.67927}},{"facility":"Medical Oncology Associates of Augusta","city":"Augusta","state":"Georgia","zip":"30901","country":"United States","geoPoint":{"lat":33.47097,"lon":-81.97484}},{"facility":"Northeast Georgia Medical Center","city":"Gainesville","state":"Georgia","zip":"30501","country":"United States","geoPoint":{"lat":34.29788,"lon":-83.82407}},{"facility":"Wellstar Cancer Research","city":"Marietta","state":"Georgia","zip":"30060","country":"United States","geoPoint":{"lat":33.9526,"lon":-84.54993}},{"facility":"Providence Medical Group","city":"Terre Haute","state":"Indiana","zip":"47802","country":"United States","geoPoint":{"lat":39.4667,"lon":-87.41391}},{"facility":"RHHP/Hope Cancer Center","city":"Terre Haute","state":"Indiana","zip":"47802","country":"United States","geoPoint":{"lat":39.4667,"lon":-87.41391}},{"facility":"Baptist Hospital East","city":"Louisville","state":"Kentucky","zip":"40207","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Norton Cancer Institute","city":"Louisville","state":"Kentucky","zip":"40207","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Hematology Oncology Life Center","city":"Alexandria","state":"Louisiana","zip":"71301","country":"United States","geoPoint":{"lat":31.31129,"lon":-92.44514}},{"facility":"Hematology Oncology Clinic, LLP","city":"Baton Rouge","state":"Louisiana","zip":"70806","country":"United States","geoPoint":{"lat":30.44332,"lon":-91.18747}},{"facility":"Center for Cancer and Blood Disorders","city":"Bethesda","state":"Maryland","zip":"20817","country":"United States","geoPoint":{"lat":38.98067,"lon":-77.10026}},{"facility":"Jackson Oncology Associates","city":"Jackson","state":"Mississippi","zip":"39202","country":"United States","geoPoint":{"lat":32.29876,"lon":-90.18481}},{"facility":"St. Louis Cancer Care","city":"Chesterfield","state":"Missouri","zip":"63017","country":"United States","geoPoint":{"lat":38.66311,"lon":-90.57707}},{"facility":"Nebraska Methodist Cancer Center","city":"Omaha","state":"Nebraska","zip":"68114","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Portsmouth Regional Hospital","city":"Portsmouth","state":"New Hampshire","zip":"03801","country":"United States","geoPoint":{"lat":43.07704,"lon":-70.75766}},{"facility":"Hematology Oncology Associates of Northern NJ","city":"Morristown","state":"New Jersey","zip":"07960","country":"United States","geoPoint":{"lat":40.79677,"lon":-74.48154}},{"facility":"New Mexico Oncology Hematology Consultants","city":"Albuquerque","state":"New Mexico","zip":"87109","country":"United States","geoPoint":{"lat":35.08449,"lon":-106.65114}},{"facility":"Cancer Care of Western North Carolina","city":"Asheville","state":"North Carolina","zip":"28801","country":"United States","geoPoint":{"lat":35.60095,"lon":-82.55402}},{"facility":"Oncology Hematology Care","city":"Cincinnati","state":"Ohio","zip":"45242","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Associates in Hematology Oncology","city":"Chattanooga","state":"Tennessee","zip":"37404","country":"United States","geoPoint":{"lat":35.04563,"lon":-85.30968}},{"facility":"Chattanooga Oncology Hematology Associates","city":"Chattanooga","state":"Tennessee","zip":"37404","country":"United States","geoPoint":{"lat":35.04563,"lon":-85.30968}},{"facility":"Tennessee Oncology, PLLC","city":"Nashville","state":"Tennessee","zip":"37023","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Peninsula Cancer Institute","city":"Newport News","state":"Virginia","zip":"23601","country":"United States","geoPoint":{"lat":36.98038,"lon":-76.42975}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Docetaxel/Carboplatin/Bevacizumab/Erlotinib","description":"Docetaxel/Carboplatin/Bevacizumab/Erlotinib: Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1 Bevacizumab 15mg/kg IV D1\n\nDocetaxel should be administered before carboplatin.\n\nAfter completion of four cycles of treatment, patients in Cohort A will then proceed with Maintenance treatment defined as follows:\n\nMaintenance Treatment for patients in Cohort A:\n\nBevacizumab 15mg/kg IV D1 Erlotinib 150mg PO daily\n\nTreatment cycle = 21 days. Patients will complete 8 cycles (24 weeks) of maintenance therapy unless there is evidence of disease recurrence or unacceptable toxicity."},{"id":"FG001","title":"Docetaxel and Carboplatin","description":"Docetaxel/Carboplatin: Adjuvant Treatment Cohort B:\n\nDocetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1\n\nDocetaxel should be administered before carboplatin.\n\nTreatment cycle = 21 days. Patients in Cohort B will complete 4 cycles of treatment."}],"periods":[{"title":"Adjuvant Treatment","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"55"},{"groupId":"FG001","numSubjects":"57"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"52"},{"groupId":"FG001","numSubjects":"47"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"10"}]}]},{"title":"Maintenance Treatment","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"3 patients came off study between the end of adjuvant therapy and the start of maintenance","numSubjects":"49"},{"groupId":"FG001","comment":"Per protocol, only the Docetaxel/Carboplatin/Bevacizumab/Erlotinib arm enters maintenance therapy","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All patients on-study","groups":[{"id":"BG000","title":"Docetaxel/Carboplatin/Bevacizumab/Erlotinib","description":"Docetaxel/Carboplatin/Bevacizumab/Erlotinib: Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1 Bevacizumab 15mg/kg IV D1\n\nDocetaxel should be administered before carboplatin.\n\nAfter completion of four cycles of treatment, patients in Cohort A will then proceed with Maintenance treatment defined as follows:\n\nMaintenance Treatment for patients in Cohort A:\n\nBevacizumab 15mg/kg IV D1 Erlotinib 150mg PO daily\n\nTreatment cycle = 21 days. Patients will complete 8 cycles (24 weeks) of maintenance therapy unless there is evidence of disease recurrence or unacceptable toxicity."},{"id":"BG001","title":"Docetaxel and Carboplatin","description":"Docetaxel/Carboplatin: Adjuvant Treatment Cohort B:\n\nDocetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1\n\nDocetaxel should be administered before carboplatin.\n\nTreatment cycle = 21 days. Patients in Cohort B will complete 4 cycles of treatment."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"55"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"112"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"64","lowerLimit":"42","upperLimit":"79"},{"groupId":"BG001","value":"64","lowerLimit":"48","upperLimit":"87"},{"groupId":"BG002","value":"64","lowerLimit":"42","upperLimit":"87"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"55"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"57"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"55"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"112"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Disease-free Survival","description":"The length of time, in months, that patients were alive from the end of their treatment without any signs or symptoms of their disease.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"1 year","groups":[{"id":"OG000","title":"Docetaxel/Carboplatin/Bevacizumab/Erlotinib","description":"Docetaxel/Carboplatin/Bevacizumab/Erlotinib: Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1 Bevacizumab 15mg/kg IV D1\n\nDocetaxel should be administered before carboplatin.\n\nAfter completion of four cycles of treatment, patients in Cohort A will then proceed with Maintenance treatment defined as follows:\n\nMaintenance Treatment for patients in Cohort A:\n\nBevacizumab 15mg/kg IV D1 Erlotinib 150mg PO daily\n\nTreatment cycle = 21 days. Patients will complete 8 cycles (24 weeks) of maintenance therapy unless there is evidence of disease recurrence or unacceptable toxicity."},{"id":"OG001","title":"Docetaxel and Carboplatin","description":"Docetaxel/Carboplatin: Adjuvant Treatment Cohort B:\n\nDocetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1\n\nDocetaxel should be administered before carboplatin.\n\nTreatment cycle = 21 days. Patients in Cohort B will complete 4 cycles of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"57"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Median DFS cannot be calculated for this arm - not enough participants with events required for this calculation"},{"groupId":"OG001","value":"55.1","lowerLimit":"32.9","upperLimit":"NA","comment":"Upper bound of 95% CI cannot be calculated for this arm"}]}]}]},{"type":"SECONDARY","title":"Safety","description":"Adverse Events occuring in \\>15% of patients","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"2 years","groups":[{"id":"OG000","title":"Docetaxel/Carboplatin/Bevacizumab/Erlotinib","description":"Docetaxel/Carboplatin/Bevacizumab/Erlotinib: Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1 Bevacizumab 15mg/kg IV D1\n\nDocetaxel should be administered before carboplatin.\n\nAfter completion of four cycles of treatment, patients in Cohort A will then proceed with Maintenance treatment defined as follows:\n\nMaintenance Treatment for patients in Cohort A:\n\nBevacizumab 15mg/kg IV D1 Erlotinib 150mg PO daily\n\nTreatment cycle = 21 days. Patients will complete 8 cycles (24 weeks) of maintenance therapy unless there is evidence of disease recurrence or unacceptable toxicity."},{"id":"OG001","title":"Docetaxel and Carboplatin","description":"Docetaxel/Carboplatin: Adjuvant Treatment Cohort B:\n\nDocetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1\n\nDocetaxel should be administered before carboplatin.\n\nTreatment cycle = 21 days. Patients in Cohort B will complete 4 cycles of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"57"}]}],"classes":[{"title":"Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"41"}]}]},{"title":"Nausea","categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"36"}]}]},{"title":"Diarrhea","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"}]}]},{"title":"Anemia","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"28"}]}]},{"title":"Neutrophil count decreased","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"26"}]}]},{"title":"White blood cell decreased","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"27"}]}]},{"title":"Alopecia","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"}]}]},{"title":"Pain","categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"15"}]}]},{"title":"Platelet count decreased","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"20"}]}]},{"title":"Constipation","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"18"}]}]},{"title":"Dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"17"}]}]},{"title":"Anorexia","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"18"}]}]},{"title":"Hyperglycemia","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"11"}]}]},{"title":"Dysgeusia","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"14"}]}]},{"title":"Mucositis","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"}]}]},{"title":"Vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"13"}]}]},{"title":"Cough","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"8"}]}]},{"title":"Peripheral sensory neuropathy","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"2-year Survival","description":"Proportion of patients known to still be alive 2 years after coming on study","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"24 months","groups":[{"id":"OG000","title":"Docetaxel/Carboplatin/Bevacizumab/Erlotinib","description":"Docetaxel/Carboplatin/Bevacizumab/Erlotinib: Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1 Bevacizumab 15mg/kg IV D1\n\nDocetaxel should be administered before carboplatin.\n\nAfter completion of four cycles of treatment, patients in Cohort A will then proceed with Maintenance treatment defined as follows:\n\nMaintenance Treatment for patients in Cohort A:\n\nBevacizumab 15mg/kg IV D1 Erlotinib 150mg PO daily\n\nTreatment cycle = 21 days. Patients will complete 8 cycles (24 weeks) of maintenance therapy unless there is evidence of disease recurrence or unacceptable toxicity."},{"id":"OG001","title":"Docetaxel and Carboplatin","description":"Docetaxel/Carboplatin: Adjuvant Treatment Cohort B:\n\nDocetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1\n\nDocetaxel should be administered before carboplatin.\n\nTreatment cycle = 21 days. Patients in Cohort B will complete 4 cycles of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"57"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.2"},{"groupId":"OG001","value":"71.9"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"The Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"18 months","groups":[{"id":"OG000","title":"Docetaxel/Carboplatin/Bevacizumab/Erlotinib","description":"Docetaxel/Carboplatin/Bevacizumab/Erlotinib: Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1 Bevacizumab 15mg/kg IV D1\n\nDocetaxel should be administered before carboplatin.\n\nAfter completion of four cycles of treatment, patients in Cohort A will then proceed with Maintenance treatment defined as follows:\n\nMaintenance Treatment for patients in Cohort A:\n\nBevacizumab 15mg/kg IV D1 Erlotinib 150mg PO daily\n\nTreatment cycle = 21 days. Patients will complete 8 cycles (24 weeks) of maintenance therapy unless there is evidence of disease recurrence or unacceptable toxicity."},{"id":"OG001","title":"Docetaxel and Carboplatin","description":"Docetaxel/Carboplatin: Adjuvant Treatment Cohort B:\n\nDocetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1\n\nDocetaxel should be administered before carboplatin.\n\nTreatment cycle = 21 days. Patients in Cohort B will complete 4 cycles of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"57"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Median OS cannot be calculated for this arm - not enough participants with events required for this calculation"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Median OS cannot be calculated for this arm - not enough participants with events required for this calculation"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Docetaxel/Carboplatin/Bevacizumab/Erlotinib","description":"Docetaxel/Carboplatin/Bevacizumab/Erlotinib: Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1 Bevacizumab 15mg/kg IV D1\n\nDocetaxel should be administered before carboplatin.\n\nAfter completion of four cycles of treatment, patients in Cohort A will then proceed with Maintenance treatment defined as follows:\n\nMaintenance Treatment for patients in Cohort A:\n\nBevacizumab 15mg/kg IV D1 Erlotinib 150mg PO daily\n\nTreatment cycle = 21 days. Patients will complete 8 cycles (24 weeks) of maintenance therapy unless there is evidence of disease recurrence or unacceptable toxicity.","seriousNumAffected":14,"seriousNumAtRisk":55,"otherNumAffected":53,"otherNumAtRisk":55},{"id":"EG001","title":"Docetaxel and Carboplatin","description":"Docetaxel/Carboplatin: Adjuvant Treatment Cohort B:\n\nDocetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1\n\nDocetaxel should be administered before carboplatin.\n\nTreatment cycle = 21 days. Patients in Cohort B will complete 4 cycles of treatment.","seriousNumAffected":14,"seriousNumAtRisk":57,"otherNumAffected":55,"otherNumAtRisk":57}],"seriousEvents":[{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":55},{"groupId":"EG001","numAffected":2,"numAtRisk":57}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":55},{"groupId":"EG001","numAffected":1,"numAtRisk":57}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":55},{"groupId":"EG001","numAffected":2,"numAtRisk":57}]},{"term":"Thromboembolic event","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":55},{"groupId":"EG001","numAffected":1,"numAtRisk":57}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":55},{"groupId":"EG001","numAffected":1,"numAtRisk":57}]},{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":55},{"groupId":"EG001","numAffected":0,"numAtRisk":57}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":55},{"groupId":"EG001","numAffected":0,"numAtRisk":57}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":55},{"groupId":"EG001","numAffected":0,"numAtRisk":57}]},{"term":"Bone infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":55},{"groupId":"EG001","numAffected":1,"numAtRisk":57}]},{"term":"Bronchial fistula","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":55},{"groupId":"EG001","numAffected":0,"numAtRisk":57}]},{"term":"Bronchial infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":55},{"groupId":"EG001","numAffected":1,"numAtRisk":57}]},{"term":"Gastrointestinal disorders - Other, hemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":55},{"groupId":"EG001","numAffected":0,"numAtRisk":57}]},{"term":"Hepatobiliary disorders - Other, cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":55},{"groupId":"EG001","numAffected":0,"numAtRisk":57}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":55},{"groupId":"EG001","numAffected":0,"numAtRisk":57}]},{"term":"Infections and infestations - Other, haemophilus influenza","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":55},{"groupId":"EG001","numAffected":1,"numAtRisk":57}]},{"term":"Infections and infestations - Other, pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":55},{"groupId":"EG001","numAffected":0,"numAtRisk":57}]},{"term":"Infections and infestations - Other, pseudomona bacteremia","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":55},{"groupId":"EG001","numAffected":0,"numAtRisk":57}]},{"term":"Infections and infestations - Other, unspecified","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":55},{"groupId":"EG001","numAffected":1,"numAtRisk":57}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":55},{"groupId":"EG001","numAffected":1,"numAtRisk":57}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":55},{"groupId":"EG001","numAffected":1,"numAtRisk":57}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":55},{"groupId":"EG001","numAffected":0,"numAtRisk":57}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":55},{"groupId":"EG001","numAffected":0,"numAtRisk":57}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":55},{"groupId":"EG001","numAffected":0,"numAtRisk":57}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":55},{"groupId":"EG001","numAffected":1,"numAtRisk":57}]}],"otherEvents":[{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":55},{"groupId":"EG001","numAffected":41,"numAtRisk":57}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":32,"numAtRisk":55},{"groupId":"EG001","numAffected":36,"numAtRisk":57}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":55},{"groupId":"EG001","numAffected":24,"numAtRisk":57}]},{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":55},{"groupId":"EG001","numAffected":28,"numAtRisk":57}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":55},{"groupId":"EG001","numAffected":26,"numAtRisk":57}]},{"term":"White blood cell decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":55},{"groupId":"EG001","numAffected":27,"numAtRisk":57}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":55},{"groupId":"EG001","numAffected":21,"numAtRisk":57}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":55},{"groupId":"EG001","numAffected":15,"numAtRisk":57}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":55},{"groupId":"EG001","numAffected":20,"numAtRisk":57}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":55},{"groupId":"EG001","numAffected":18,"numAtRisk":57}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":55},{"groupId":"EG001","numAffected":17,"numAtRisk":57}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":55},{"groupId":"EG001","numAffected":18,"numAtRisk":57}]},{"term":"Hyperglycemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":55},{"groupId":"EG001","numAffected":11,"numAtRisk":57}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":55},{"groupId":"EG001","numAffected":14,"numAtRisk":57}]},{"term":"Mucositis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":55},{"groupId":"EG001","numAffected":12,"numAtRisk":57}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":55},{"groupId":"EG001","numAffected":13,"numAtRisk":57}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":55},{"groupId":"EG001","numAffected":8,"numAtRisk":57}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":55},{"groupId":"EG001","numAffected":2,"numAtRisk":57}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":55},{"groupId":"EG001","numAffected":3,"numAtRisk":57}]},{"term":"Gastroesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":55},{"groupId":"EG001","numAffected":7,"numAtRisk":57}]},{"term":"Fever","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":55},{"groupId":"EG001","numAffected":6,"numAtRisk":57}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":55},{"groupId":"EG001","numAffected":4,"numAtRisk":57}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":55},{"groupId":"EG001","numAffected":5,"numAtRisk":57}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":55},{"groupId":"EG001","numAffected":5,"numAtRisk":57}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":55},{"groupId":"EG001","numAffected":5,"numAtRisk":57}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":55},{"groupId":"EG001","numAffected":4,"numAtRisk":57}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":55},{"groupId":"EG001","numAffected":5,"numAtRisk":57}]},{"term":"General disorders and administration site conditions - Other, hemorrhage","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":55},{"groupId":"EG001","numAffected":3,"numAtRisk":57}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":55},{"groupId":"EG001","numAffected":3,"numAtRisk":57}]},{"term":"Hypoalbuminemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":55},{"groupId":"EG001","numAffected":4,"numAtRisk":57}]},{"term":"Skin and subcutaneous tissue disorders - Other","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":55},{"groupId":"EG001","numAffected":3,"numAtRisk":57}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":55},{"groupId":"EG001","numAffected":4,"numAtRisk":57}]},{"term":"Musculoskeletal and connective tissue disorders - Other, body ache","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":55},{"groupId":"EG001","numAffected":6,"numAtRisk":57}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":55},{"groupId":"EG001","numAffected":4,"numAtRisk":57}]},{"term":"Allergic rhinitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":55},{"groupId":"EG001","numAffected":3,"numAtRisk":57}]},{"term":"Infections and infestations - Other, unknown","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":55},{"groupId":"EG001","numAffected":6,"numAtRisk":57}]},{"term":"Weight loss","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":55},{"groupId":"EG001","numAffected":3,"numAtRisk":57}]},{"term":"Allergic reaction","organSystem":"Immune system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":55},{"groupId":"EG001","numAffected":2,"numAtRisk":57}]},{"term":"Hyponatremia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":55},{"groupId":"EG001","numAffected":4,"numAtRisk":57}]},{"term":"Respiratory, thoracic and mediastinal disorders - Other, unknown","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":55},{"groupId":"EG001","numAffected":2,"numAtRisk":57}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The sponsor can review/embargo results communications prior to public release for a period that is \\>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites"},"pointOfContact":{"title":"John D Hainsworth, MD","organization":"Sarah Cannon Research Institute","email":"asksarah@scresearch.net","phone":"1-877-691-7274"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077143","term":"Docetaxel"},{"id":"D016190","term":"Carboplatin"}],"ancestors":[{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D056831","term":"Coordination Complexes"}]}},"hasResults":true}